Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-24

FDA Approved: OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE — Original Application (Micro Labs Limited)

View source ↗

Summary

The FDA approved a fixed-dose combination tablet containing olmesartan medoxomil, amlodipine besilate, and hydrochlorothiazide under Micro Labs Limited’s origin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan medoxomil amlodipine and hydrochlorothiazide (olmesartan medoxomil; amlodipine; hydrochlorothiazide)

Snippet

ORIG AP for OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE)